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Cholesteatoma may cause bone erosion, with high 
morbidity and mortality rates. Tumor Necrosis Factor -
Alpha (TNF-a) is one of the main cytokines involved in this 
process. Our goal was to evaluate the role of TNF-a in Bone 
Resorption and its effect on cholesteatoma. Material and 
Methods: analysis and critical literature review. Results: 
Different studies have demonstrated that TNF-a is capable of 
causing bone erosion. It may stimulate the differentiation and 
maturation of osteoclasts or it may act on the bone matrix, 
exposing it to the action of the osteoclasts. It is possible to 
inhibit TNF-a, reducing its effects and prevent bone loss in 
illnesses such as rheumatoid arthritis,and there has been no 
specific investigation regarding cholesteatomas. All studies 
agree on the importance of TNF-a in the bone resorption 
process present in cholesteatomas, and on the degree of 
destruction observed; however, there is no consensus as to its 
location. These differences are probably due to receptor site. 
Conclusion: TNF-a, present in cholesteatomas, promotes 
bone resorption, along with other cytokines (RANKL and 
IL-1) related to complications.
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INTRODUCTION
Acquired middle ear cholesteatoma was first des-
cribed by Curveilhier in 1829. It is characterized by the 
invasion of keratinized stratified squamous epithelium into 
the tympanic cavity. This epithelium is different from that 
usually found in the middle ear.1
Cholesteatoma may cause bone destruction and 
result in intratemporal and intracranial complications,2 
which have high morbidity and mortality rates. This jus-
tifies our study of the bone destruction mechanisms in 
cholesteatoma.
There are numerous theories to explain the des-
tructive properties (erosion) of cholesteatomas. Pressure 
due to accumulated keratin and other waste was initially 
proposed as the cause of destruction. A biochemical 
theory eventually was postulated, in which enzymes and 
cytokines released by cholesteatomas would cause bone 
lysis and destruction.3
Cytokines are a group of low molecular weight 
proteins for communication between cells.4 Cytokines are 
released as a result of a variety of stimuli, and interact with 
their receptors to regulate cell function.5 They are closely 
related to inflammation. The tumor necrosis factor alpha 
(TNF-α) was discovered by Carswell et al.6 in 1975; it is 
considered one of the main cytokines related to inflam-
mation and immune processes, and operates in various 
parts of the body. TNF-α is secreted by macrophages, 
lymphocytes and monocytes mostly as a result of the pre-
sence of bacterial lipopolysaccharides (LPS). TNF-α and 
other cytokines cause bone destruction and remodelling7 
in cholesteatomas.
The aim of this paper is to analyze the importance 
of tumor necrosis factor alpha (TNF-α) in bone resorption 
and its action in acquired middle ear cholesteatoma based 




TNF-α is produced by activated macrophages, lym-
phocytes or monocytes.8 The main stimulus for its produc-
tion are lipopolysaccharides that are part of gram-negative 
bacterial membranes.9 After production and release, TNF-α 
links to specific receptors called TNF receptors I and II 
(TNF-R) to produce biological effects. TNF receptors (par-
ticularly TNF-RII) may also initiate apoptosis. The mecha-
nism that defines the dominant effect, however, has not 
been fully clarified.5 Thus, the main physiological effect of 
TNF-α is to promote the immunological and inflammatory 
response by recruiting neutrophils and monocytes to an 
infection site followed by their activation. TNF-α therefore 
has a number of effects in the body.5
When released at low concentrations, TNF-α acts 
on endothelial cells to promote vasodilation and stimula-
tes these cells to secrete a group of leukocyte-chemotaxis 
cytokines named chemokines. Resulting local inflammation 
combats infections.5 In the hypothalamus TNF-α is an 
endogenous pyrogen that causes fever. In the liver, TNF-
α stimulates the production of acute phase inflammatory 
proteins and fibrinogen.5
TNF-α leads to bone destruction by acting directly 
on osteoclast differentiation and maturation, and  by indi-
rectly exposing the bone matrix.10 It does so together with 
interleukin 1 (IL-1) and RANKL (ligandins for activating 
NF-κB receptors), which are also abundant in inflamma-
tion sites associated with bone destruction. Together, 
these substances can recruit, differentiate, and activate 
osteoclasts.11 There is, therefore, synergy between TNF-α 
and RANKL that increases osteoclast function by a coope-
ration mechanism,8,12 to which may be added interleukin 
1 and 6 (IL-1 and IL-6).13,14
TNF-α may be inhibited by antagonist solutions 
containing a soluble portion that block its receptors. As-
suma et al.12 (1998) observed a roughly 60% reduction of 
bone loss by using these antagonists. TNF-α may also be 
inhibited by anti-TNF-α antibodies.15
 
Action of TNF-α in acquired middle ear cholesteatoma
The first papers that investigated the role of TNF-α 
in cholesteatoma were published in the beginning of the 
1990s.16,17 Since then many authors have studied the action 
of TNF-÷ on bone resorption in cholesteatoma.18
Yan and Huang11 (1991) analyzed five experimen-
tally induced cholesteatomas in animals and five surgical 
fragments. They found that human and experimental cho-
lesteatomas had varying degrees of inflammation, including 
mononuclear infiltrates (lymphocytes and macrophages) 
and signs of vascular proliferation. Immunohistochemistry 
demonstrated TNF-α in granulation tissue. The authors 
noted that adding TNF-α to bone tissue cultures stimu-
lated the formation of multinucleated cells (osteoclasts) 
that produced a gap on the bone surface (Howship’s 
lacunae). They concluded that TNF-α is present in gra-
nulation tissue adjacent to the cholesteatoma and causes 
bone resorption11.
Marenda and Aufdemorte19 (1995) attempted to find 
TNF-α and other cytokines in surgically collected choleste-
atomas, comparing them with normal skin fragments from 
the external auditory meatus (EAM). TNF-α was found in 
suprabasal layers of cholesteatomas and in macrophages 
and fibroblasts; it was not found in the basal layer or in 
the EAM.
Amar et al.20 (1996) studied bone destruction in cho-
lesteatoma by dosing the TNF-α concentration in patients 
undergoing surgery. They also subdivided cholesteatomas 
into two groups: local and extended (based on the number 
of eroded ossicles, the presence of facial canal erosion, 
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exposure of the dura mater and the sigmoid sinus). TNF-
αconcentration was significantly higher in more aggres-
sive cholesteatomas. Amar et al.20 (1996) concluded that 
cytokines - TNF-α in particular - are directly involved in 
bone destruction caused by cholesteatomas, acting as an 
autocrine growth factor and indirectly stimulating hydro-
lase lysozymes.
Chung and Yoon21 (1998) separated the subepithe-
lial and epithelial portion of cholesteatomas and cultured 
these tissues. These authors found that epithelial cells 
only produced interleukins (cytokines similar in function 
to TNF-α) when associated with the subepithelial tissue. 
They concluded that substances from the perimatrix pos-
sibly stimulate the cholesteatoma matrix to produce IL1, 
resulting in bone resorption.
Sastry et al.7 (1999) dosed serum TNF-α levels in 
twenty normal patients (control group) and in twenty pa-
tients that were to undergo surgery for middle ear choleste-
atoma. They collected surgical fragments of cholesteatomas 
and noted the degree of bone destruction. According to 
their findings, patients undergoing otological surgery had 
significantly higher preoperative serum TNF-α levels. They 
also found differences in serum TNF-α levels depending 
on the degree of bone destruction.
Akimoto et al.22 (2000) studied the role of TNF-α in 
inflammation in congenital and acquired cholesteatomas. 
They noted that TNF-α and IL-1 levels are higher in these 
conditions compared to the skin of the EAM.
Yong-Soo et al.13 (2001) also attempted to identify 
the importance of TNF-α in middle ear inflammation in rats 
with secretory otitis media induced by injecting Psudomo-
nas aeuroginosas endotoxins. They noted the possibility 
of inhibiting inflammation. This was done dividing the 
rats into two groups. Saline solution containing a TNF-α 
antagonist (sTNF RI) was injected in rats belonging to the 
first group; rats in the second group received no injection. 
The authors found that the concomitant injection of sTNF 
RI inhibited inflammation. According to these authors, a 
TNF-α antagonist could be an important measure in the 
treatment of secretory otitis media, avoiding complications 
and cholesteatomas.
Yetiser et al.23 (2002) compared TNF-α and IL-1 
levels in sixteen cholesteatoma-free chronic otitis media 
patients and twenty chronic otitis media patients with 
cholesteatomas. They found significantly higher levels of 
IL-1 and TNF-α in the second group, and concluded that 
bone destruction was mediated by these cytokines.
Alves and Ribeiro18 (2004) reviewed the role of 
cytokines in acquired middle ear cholesteatoma. They 
found a lack of consensus in literature about the localiza-
tion of TNF-α in cholesteatoma layers. According to these 
authors TNF-α acts as a mediator in bone destruction.
DISCUSSION
Cytokines are proteins formed within cells that, 
when released, interact with transmembrane cell receptors 
to produce their biological effect.4 Depending on the site 
of action, they may have an autocrine action (when acting 
within their mother cell), a paracrine action (when acting 
on neighboring cells), or an endocrine action (acting at a 
distance). Each cytokine has multiple actions (pleiotropic 
effect), operating in synergy or antagonism, such as the 
synergism between TNF-α and interleukin 1 (IL-1), the 
main cytokines released in inflammation.4,5
TNF-α is produced by activated macrophages or 
by lymphocytes and monocytes. After linking with its 
receptors, TNF-α stimulates transcription and production 
of the IκB kinase enzyme, which in turn produces the 
nuclear factor κB (NF-κB). When activated, NF-κb acts 
on the cell nucleus inducing the production of a variety 
of proteins involved in inflammation and immunological 
processes responsible for the biological action of TNF-α.8 
(Figure 1).
Figure 1. Action of TNF-α on a cell. After linking to its receptor, TNF-α 
activates NF-κB, which produces and releases a variety of substances 
involved in inflammation and the immunological response.
Studies on the effect of TNF-α in cholesteatoma 
started in the beginning of the 1990s, when TNF-α was 
observed in that condition.16,17 Yan and Huang11 (1991) 
noted that adding a prepared supernatant of cholesteatoma 
fragments to a bone tissue culture stimulated the formation 
of multinucleated cells and the appearance of surface lacu-
nae. Multinucleated cells were in fact the osteoclasts found 
in lacunae (Howship’s lacunae) and responsible for bone 
destruction. It was then demonstrated that cholesteatomas 
can lead to bone resorption by releasing TNF-α. Blocking 
TNF-α reduces bone resorption.8,14,22 All of the authors 
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we reviewed agree that TNF-α is one of the main factors 
responsible for bone resorption and destruction seen in 
diseases that course together with chronic inflammation.
Osteoclasts are the main cells involved in bone re-
sorption. They originate from monocytes and macrophages 
and act directly on the bone matrix, causing bone erosion 
and remodeling. TNF-α, IL-6, IL-1 α or β, interleukin 11 
(IL-11), and the macrophage colony stimulating factor (M-
CSF) are all responsible for osteoclast differentiation and 
regulation. These factors, therefore, act directly on bone 
resorption.8,10,12
Other factors, however, have an indirect action 
on osteoclasts or on bone-lining cells, by exposing the 
bone matrix to osteoclasts. These include the parathyroid 
hormone, prostaglandins, estrogen, IL-11, IL-1 α or β, and 
TNF- α (which acts both directly and indirectly).10,12
Osteoblasts release a substance - RANKL - that sti-
mulates differentiation of macrophages into osteoclasts. 
There is synergy between TNF-α and RANKL in that both 
cooperate to increase the action of osteoclasts.11 Authors 
that have studied TNF-α action mechanisms believe that 
it promotes bone resorption by two pathways (direct and 
indirect),8,10,12 interacting with other cytokines (RANKL and 
IL-1) in this process.11,13
All of the authors we reviewed agree that TNF-α 
is present in cholesteatomas. There is no consensus, ho-
wever, about its localization. Alves and Ribeiro18 (2004) 
summarized the differences in opinion. (Table 1)
the cholesteatoma epithelium (matrix). Sufficient studies 
to prove the location of TNF-α receptors in cholesteatoma 
and the factors that enhance its expression are lacking in 
literature.
The quantity of TNF-α, and not only the number of 
receptors, also seems to be related to bone destruction. 
Various authors have attempted to relate TNF-α levels 
with intraoperative findings.7,20,23 Cholesteatomas with 
increased bone destruction had a higher local amount of 
TNF-α,7,20,23 a finding seen both in acquired and congenital 
cholesteatomas.22 There is, however, only one published 
paper comparing congenital and acquired cholesteatomas, 
so this last findings needs to be further substantiated. The 
plasmatic concentration of TNF-α in cholesteatoma patients 
with variable degrees of bone destruction is proportionally 
higher compared to normal patients. A correlation may be 
established between systemic TNF-α levels and its local 
behavior.7 In future it may become possible to predict 
the aggressiveness of cholesteatoma through a blood test, 
predicting the associated degree of bone destruction and 
the possibility of complications.
Based on these papers, we may conclude that 
TNF-α is associated with bone destruction and defines 
its severity.7,20,23 TNF-α is increased both systemically and 
locally in aggressive cholesteatomas. None of the authors, 
however, investigated why TNF-α levels are increased. The 
difference in TNF-α levels may be related to various other 
factors such as, for instance, duration of the disease, the 
intensity of local infection, or the presence and distribution 
of TNF-α receptors in the cholesteatoma matrix. There are, 
however, insufficient published papers for a more detailed 
analysis of this hypothesis.
TNF-α is one of the main factors responsible for 
bone resorption and resulting complications in a variety 
of diseases. The possibility of interrupting the inflamma-
tion seen in such chronic diseases was raised following 
the discovery of natural inhibitors against TNF-α, which 
could reduce morbidity and mortality.24-26 The first large-
scale clinical trial of these inhibitors in systemic diseases 
demonstrated the efficacy of this treatment in reducing 
bone resorption.27 Studies have focused on inhibiting 
bone destruction by blocking the action of TNF-α using 
TNF-α antagonists or anti-TNF-α antibodies.
In periodontitis injection of a solution containing a 
TNF-α antagonist (s NF RI) inhibits osteoclast formation, 
reduces inflammatory cell recruitment and reduces bone 
loss by 60%.12,28 Thus, TNF-α antagonists can reduce bone 
destruction.
Anti-TNF-α antibodies can also reduce and pos-
tpone bone destruction in rheumatoid arthritis.27 Bone 
resorption may, therefore, be inhibited using two different 
pathways. There are, however, no such studies applied 
to cholesteatoma. Based on these findings, there may be 
in future a medical treatment to inhibit inflammation and 
Table 1. Location of TNF-α in cholesteatoma, according to various 
authors.
Authors Matrix Perimatrix





Sastry et al.7 All layers Negative
Akimoto et al.22 Negative Positive
Source: Based on work by Alves and Ribeiro18 (2004)
TNF-α is released in all middle ear infections, not 
only in cholesteatoma.17,23 In other chronic infections of 
the ear, however, the bone destruction seen in choleste-
atoma is not observed. Chung and Yoon (1998)21 noted 
that interleukin (that stimulates the cholesteatoma matrix 
to cause bone destruction) is released in the perimatrix. 
Bone destruction is not seen when the epithelial tissue 
(matrix) is separated from the subepithelial tissue (perima-
trix) in cholesteatoma. The difference may be explained 
by the presence and distribution of TNF-α receptors in 
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control bone destruction, which would reduce the mor-
bidity and mortality of cholesteatoma.
CONCLUSION
TNF-α is found in cholesteatomas, promoting bone 
resorption by different routes. It acts on osteoclast differen-
tiation and maturation (direct pathway) and also exposes 
the bone matrix (indirect pathway). TNF-α, however, is 
not the only factor involved in bone resorption; it acts in 
association with interleukin 1 and RANKL. Furthermore, 
local levels of TNF-α are related with the degree of bone 
destruction in this disease.
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